Monoclonal Antibodies Specific for a Conformationally Altered State of Fibrinogen^[*]

Summary

Four monoclonal antibodies were selected by their ability to discriminate surface-bound from soluble fibrinogen. These antibodies reacted with insolubilized fibrinogen but not other immobilized proteins and their reaction with surface-bound fibrinogen was not diminished by a 100-fold excess of sotuble fibrinogen. The antibodies reacted with the same or spatially proximal epitopes, and the recognized epitope(s) resided within the gamma chain segment of the D domain of fibrinogen. Fab fragments of the antibodies inhibited fibrin polymerization in a dose dependent manner, suggesting that the epitope(s) was also exposed by the conversion of fibrinogen to fibrin. These data indicate that adsorption of fibrinogen onto a surface induces conformational changes and that similar changes are also evoked when fibrinogen is converted into fibrin.

Dedicated to Professor M. Verstraete on the occasion of his 65th birthday

• References

• 1 Doolittle RF. Fibrinogen and fibrin. Annu Rev Biochem 1984; 53: 195-229
• 2 Marder VJ. Molecular aspects of fibrin formation and dissolution. In: Seminars in Thrombosis and Hemostasis. Vol. 8, No. 1 Thieme-Stratton Inc; New York: 1982: 2-73
• 3 Dang CV, Bell WR, Schuman M. The normal and morbid biology of fibrinogen. Am J Med 1989; 87: 567-576
• 4 Plow EF, Edgington TS. Surface markers of fibrinogen and its physiologic derivatives revealed by antibodies probes. Semin Thromb Hemostas 1982; 8: 36-56
• 5 Kudryk BJ, Grossman ZD, McAfee JG, Rosebrough SF. Monoclonal antibodies as probes for fibrin(ogen) proteolysis. In: Monoclonal Antibodies in Immunoscintigraphy Chatal J-F. (ed). CRC Press; Boca Raton: 1989. in press
• 6 Hui KY, Haber E, Matsueda GR. Monoclonal antibodies to a synthetic fibrin-like peptide bind to human fibrin but not fibrinogen. Science 1983; 222: 1129-1132
• 7 Kudryk B, Rohoza A, Amadi M, Chin J, Wiebe ME. Specificity of a monoclonal antibody for the NH2-terminal region of fibrin. Mol Immunol 1984; 21: 89-94
• 8 Schielen WJ G, Voskuilen M, Tesser GI, Nieuwenhuizen W. The sequence A-alpha-(148-160) in fibrin, but not in fibrinogen is accessible to monoclonal antibodies. Proc Natl Acad Sci USA 1989; 86: 8951-8954
• 9 Morris JP, Blatt S, Powell JR, Strickland DK, Castellino FJ. Role of lysine binding regions in the kinetic properties of human plasmin. Biochemistry 1981; 20: 4811-4816
• 10 Nakane PK, Kawaoi A. Peroxidase labeled antibody: A new method of conjugation. J Histochem Cytochem 1974; 22: 1084-1091
• 11 Guesdon JL, Temynck T, Avrameas S. The use of avidin-biotin interaction of immunoenzymatic techniques. J Histochem Cytochem 1979; 27: 1131-1139
• 12 Porter RR. The hydrolysis of rabbit gamma-globulin and antibodies with crystalline papain. Biochem J 1959; 73: 119-126
• 13 Laemmli UK. Cleavage of structural proteins during the assembly of the head of bacteriophage T4. Nature 1970; 227: 680-685
• 14 Johnson DA, Gautsch JW, Sportman JR, Elder JH. Improved techniques utilizing nonfat dry milk for analysis of proteins and nucleic acids transferred to nitrocellulose. Gene Anal Tech 1984; 1: 3-8
• 15 Belitser VA, Varetskaja TV, Malneva GV. Fibrinogen-fibrin interaction. Biochim Biophys Acta 1986; 154: 367-375
• 16 Doolittle RF, Schubert D, Schwartz SA. Amino acid sequence studies on artiodactyl fibrinopeptides I. Dromedary camel, mule deer, and cape buffalo, Arch Biochem Biophys 1967; 118: 456-467
• 17 Varadi A, Scheraga HA. Localization of segments essential for polymerization and for calcium binding in the gamma-chain of human fibrinogen. Biochemistry 1986; 25: 519-528
• 1 Engvall E, Ruoslahti E. Binding of soluble form of fibroblast surface protein, fibronectin, to collagen. Int J Cancer 1977; 20: 1-5
• 19 Wolff R, Plow EF, Ginsberg MH. Interaction of thrombospondin with resting and stimulated human platelets. J Biol Chem 1986; 261: 6840-6846
• 20 Deutsch DG, Mertz ET. Plasminogen: purification from human plasma by affinity chromatography. Science 1970; 170: 1995-1996
• 21 Olexa SA, Budzynski AZ. Localization of a fibrin polymerization site. J Biol Chem 1981; 256: 3544-3549
• 22 Weisel JW, Stauffacher CV, Bullitt E, Cohen C. A model for fibrinogen: Domains and sequence. Science 1985; 230: 1388-1391
• 23 Chiu TH, Nyilas E, Turcotte LR. Microcalorimetric and electrophoretic studies of protein sorption from plasma. Trans Am Soc Artif Int Organs 1978; 24: 389
• 24 Chan B, Brash JL. Interactions of human fibrinogen with glass surface. Thromb Haemostas 1979; 42: 132 (Abstr.)
• 25 Soria J, Soria C, Mirashi M, Boucheix C, Aurengo A, Perrot J, Bemadou A, Samama M, Rosenfeld C. Conformational change in fibrinogen induced by adsorption to a surface. J Colloid Interface Sci 1985; 107: 204-208
• 26 Abrams CS, Ellison N, Budzynski A, Shattil SJ. Platelet activation and fragmentation during cardiopulmonary bypass can be detected by flow cytometry of whole blood. Blood 1987; 70: 335a
• 27 Zamarron C, Ginsberg MH, Plow EF. Receptor induced binding sites (RIBS) are exposed in fibrinogen as a consequence of its interaction with platelets. Blood 1989; 74: 208a
• 28 Ciemiewski CS, Kloczewiak M, Budzynski AZ. Expression of primary polymerization sites in the D domain of human fibrinogen depends on intact conformation. J Biol Chem 1986; 261: 9116-9121
• 29 Terukina S, Yamazumi K, Okamoto K, Yamashita H, Ito Y, Matsuda M. Fibrinogen Kyoto III: A congenital dysfibrinogen with a gamma aspartic acid-330 to tyrosine substitution manifesting impaired fibrin monomer polymerization. Blood 1989; 74: 2681-2687
• 30 Reber P, Furlan M, Rupp C, Kehl M, Henschen A, Mannucci PM, Beck EA. Characterization of fibrinogen Milano I: Amino acid exchange gamma 330-Asp - Val impairs fibrinogen polymerization. Blood 1986; 67: 1751-1756
• 31 Yamazumi K, Terukina S, Onohara S, Matsuda M. Normal plasmic cleavage of the gamma-chain variant of “fibrinogen Saga” with an Arg-275 to His substitution. Thromb Haemostas 1988; 60: 476-480
• 32 Reber P, Furlan M, Henschen A, Kaudewitz H, Barbui T, Hilgard P, Nenci GG, Berrettini M, Beck EA. Three abnormal fibrinogen variants with the same amino acid substitution (gamma 275Arg His): Fibrinogen Bergamo II, Essen and Perugia. Thromb Haemostas 1986; 56: 401-406
• 33 Yoshida N, Terukina S, Okuma M, Moroi M, Aoki N, Matsuda M. Characterization of an apparently lower molecular weight gamma-chain variant in fibrinogen Kyoto I. The replacement oi gamma-asparagine 308 by lysine which causes accelarated cleavage of fragment Di by plasmin and the generation of a new plasmin cleavage site. J Biol Chem 1988; 263: 13848-13856
• 34 Yamazumi K, Shimura KI, Terukina S, Takahashi N, Matsuda M. A gamma methionine-310 to threonine substitution and consequent N-glycosylation at gamma asparagine-308 identified in a congenital dysfibrinogenemia associated with posttraumatic bleeding, fibrinogen Asahi. J Clin Invest 1989; 83: 1590-1597
• 35 Scheefers-Borchel U, Muller-Berghaus G, Fuhge P, Eberle R, Heim-burger N. Discrimination between fibrin and fibrinogen by a monoclonal antibody against a synthetic peptide. Proc Natl Acad Sci USA 1985; 82: 7091-7095
• 36 Wasser MN J M, Koppert PW, Arndt JW, Emeis JJ, Feitsma RI J, Pauwels EK J, Nieuwenhuizen W. An antifibrin monoclonal antibody useful in immunoscintigraphic detection of thrombin. Blood 1989; 74: 708-714
• 37 Tymkowycz PM, Creighton LJ, Gascoine PS, Zanelli GD, Webbon PM, Gaffney PJ. Imaging of human thrombi in the rabbit jugular vein: Comparison of two fibrin-specific monoclonal antibodies. Thromb Res 1989; 54: 411-421
• 38 Haber E, Quertermous T, Matsueda GR, Marschall SR. Innovative approaches to plasminogen activator therapy. Science 1989; 243: 51-56